

Ana Alastruey-Izquierdo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1749649/publications.pdf>

Version: 2024-02-01

138
papers

8,150
citations

57758

44
h-index

54911

84
g-index

152
all docs

152
docs citations

152
times ranked

7199
citing authors

#	ARTICLE	IF	CITATIONS
1	Wild Boar (<i>Sus scrofa</i>) as Reservoir of Zoonotic Yeasts: Bioindicator of Environmental Quality. <i>Mycopathologia</i> , 2022, 187, 235-248.	3.1	7
2	Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. <i>European Respiratory Journal</i> , 2022, 59, 2102950.	6.7	9
3	Tackling the emerging threat of antifungal resistance to human health. <i>Nature Reviews Microbiology</i> , 2022, 20, 557-571.	28.6	311
4	Role of lizards as reservoirs of pathogenic yeasts of zoonotic concern. <i>Acta Tropica</i> , 2022, 231, 106472.	2.0	0
5	Aspergillosis by cryptic <i>Aspergillus</i> species: A case series and review of the literature. <i>Revista Iberoamericana De Micologia</i> , 2022, 39, 44-49.	0.9	4
6	Epidemiology and Mortality of Cryptococcal Disease in Guatemala: Two-Year Results of a Cryptococcal Antigen Screening Program. <i>Microorganisms</i> , 2022, 10, 1388.	3.6	3
7	Do high MICs predict the outcome in invasive fusariosis?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1063-1069.	3.0	28
8	In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of <i>Aspergillus</i> , Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies. <i>Journal of Fungi (Basel)</i> , 2021, 7, 1011.	0.5	10
9	A Rapid Screening Program for Histoplasmosis, Tuberculosis, and Cryptococcosis Reduces Mortality in HIV Patients from Guatemala. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 268.	3.5	22
10	Impact of the COVID-19 pandemic on HIV care in Guatemala. <i>International Journal of Infectious Diseases</i> , 2021, 108, 422-427.	3.3	16
11	Genotyping and In Vitro Antifungal Susceptibility Profile of <i>Neoscytalidium</i> Species Isolates from Respiratory Tract. <i>Mycopathologia</i> , 2021, 186, 833-845.	3.1	1
12	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases</i> , 2021, 21, e364-e374.	9.1	99
13	Azole resistance survey on clinical <i>Aspergillus fumigatus</i> isolates in Spain. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1170.e1-1170.e7.	6.0	34
14	Examining Signatures of Natural Selection in Antifungal Resistance Genes Across <i>Aspergillus</i> Fungi. <i>Frontiers in Fungal Biology</i> , 2021, 2, .	2.0	2
15	Updated estimated incidence and prevalence of serious fungal infections in Trinidad and Tobago. <i>IJID Regions</i> , 2021, , .	1.3	2
16	<i>Apophysomyces variabilis</i> , an emerging and worrisome cause of primary cutaneous necrotizing infections in India. <i>Journal De Mycologie Medicale</i> , 2021, 31, 101197.	1.5	6
17	Invasive Fusariosis in Nonneutropenic Patients, Spain, 2000-2015. <i>Emerging Infectious Diseases</i> , 2021, 27, 24-36.	4.3	19
18	MixInYeast: A Multicenter Study on Mixed Yeast Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 13.	3.5	14

#	ARTICLE	IF	CITATIONS
19	Incidence of Histoplasmosis in a Cohort of People with HIV: From Estimations to Reality. <i>Microorganisms</i> , 2021, 9, 2596.	3.6	13
20	Genetic diversity and antifungal susceptibility patterns of <i>Aspergillus nidulans</i> complex obtained from clinical and environmental sources. <i>Mycoses</i> , 2020, 63, 78-88.	4.0	16
21	Polyphasic identification of three new species in <i>Alternaria</i> section <i>Infectoriae</i> causing human cutaneous infection. <i>Mycoses</i> , 2020, 63, 212-224.	4.0	15
22	The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz534.	0.9	24
23	Unusual etiology of keratitis in a patient with bullous queratopathy. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 84-85.	0.3	0
24	Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 216.	3.5	21
25	Fungal co-infection in COVID-19 patients: Should we be concerned?. <i>Revista Iberoamericana De Micología</i> , 2020, 37, 41-46.	0.9	113
26	Albifimbria verrucaria keratitis: a case report. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 398-399.	0.3	1
27	Queratitis por Albifimbria verrucaria: a propósito de un caso. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 398-399.	0.5	0
28	CPAnet Registry—An International Chronic Pulmonary Aspergillosis Registry. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 216.	3.5	18
29	Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV. <i>Aids</i> , 2020, 34, 1625-1632.	2.2	23
30	Point Mutations in the 14- α Sterol Demethylase Cyp51A or Cyp51C Could Contribute to Azole Resistance in <i>Aspergillus flavus</i> . <i>Genes</i> , 2020, 11, 1217.	2.4	13
31	Draft Genome Sequences of Four <i>Aspergillus</i> Section <i>Fumigati</i> Clinical Strains. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.6	4
32	<i>In vitro</i> activity of olorofim against clinical isolates of <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> using EUCAST and CLSI methodologies. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3582-3585.	3.0	23
33	Nationwide surveillance of azole-resistant <i>Aspergillus fumigatus</i> environmental isolates in Greece: detection of pan-azole resistance associated with the TR46/Y121F/T289A cyp51A mutation. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3181-3188.	3.0	12
34	Successful treatment of invasive aspergillosis caused by <i>Aspergillus parafelis</i> in a kidney transplant recipient. <i>Medical Mycology Case Reports</i> , 2020, 30, 35-38.	1.3	1
35	Genomic and Phenotypic Heterogeneity of Clinical Isolates of the Human Pathogens <i>Aspergillus fumigatus</i> , <i>Aspergillus lentulus</i> , and <i>Aspergillus fumigatiaffinis</i> . <i>Frontiers in Genetics</i> , 2020, 11, 459.	2.3	44
36	Tracing the Evolutionary History and Global Expansion of <i>Candida auris</i> Using Population Genomic Analyses. <i>MBio</i> , 2020, 11, .	4.1	224

#	ARTICLE	IF	CITATIONS
37	Late Breaking Abstract - CPAnet Registry " An International Chronic Pulmonary Aspergillosis Registry. , 2020, , .		1
38	Queratitis de etiología inusual en paciente con queratopatía bullosa. Enfermedades Infecciosas Y Microbiología Clínica, 2020, 38, 84-85.	0.5	0
39	Detection and Control of Fungal Outbreaks. Mycopathologia, 2020, 185, 741-745.	3.1	4
40	Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 535-541.	0.5	46
41	Clinical and Laboratory Development of Echinocandin Resistance in Candida glabrata: Molecular Characterization. Frontiers in Microbiology, 2019, 10, 1585.	3.5	30
42	Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in Aspergillus Species Received within a Surveillance Program on Antifungal Resistance in Spain. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	27
43	ECMM "Candida Reg" A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
44	Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2019, 37, 535-541.	0.3	1
45	Evaluation of a Novel Mitochondrial Pan-Mucorales Marker for the Detection, Identification, Quantification, and Growth Stage Determination of Mucormycetes. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rBT /Overlock 10		
46	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
47	Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1581-1584.	2.9	28
48	A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	34
49	Emerging mould infections: Get prepared to meet unexpected fungi in your patient. Medical Mycology, 2019, 58, 156-162.	0.7	10
50	In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. Journal of Antimicrobial Chemotherapy, 2019, 74, 1586-1590.	3.0	56
51	Chronic pulmonary aspergillosis update: A year in review. Medical Mycology, 2019, 57, S104-S109.	0.7	42
52	Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: Report of two cases and comprehensive review of the literature. Transplant Infectious Disease, 2019, 21, e13072.	1.7	10
53	Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients. Expert Review of Anti-Infective Therapy, 2019, 17, 295-305.	4.4	49
54	Diversity of coelomycetous fungi in human infections: A 10-y experience of two European reference centres. Fungal Biology, 2019, 123, 341-349.	2.5	20

#	ARTICLE	IF	CITATIONS
55	Fungal epidemiology in cystic fibrosis patients with a special focus on <i>Scedosporium</i> species complex. <i>Microbial Pathogenesis</i> , 2019, 129, 168-175.	2.9	19
56	In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1295-1299.	3.0	35
57	Photo Quiz: Nasal Respiratory Difficulties and Rhinorrhea in a 16-Year-Old Female. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	0
58	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <sc>FUN</sc>gal infections Definitions in <sc>ICU</sc> patients (<sc>FUNDICU</sc>) project. <i>Mycoses</i> , 2019, 62, 310-319.	4.0	53
59	Answer to January 2019 Photo Quiz. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	0
60	<i>Neocucurbitaria keratinophila</i> : An emerging opportunistic fungus causing superficial mycosis in Spain. <i>Medical Mycology</i> , 2019, 57, 733-738.	0.7	5
61	Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in <i>Candida</i> and <i>Aspergillus</i> Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	59
62	Cutaneous lesions and hemiparesis in a kidney transplant recipient. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018, 36, 246-248.	0.3	0
63	Pharmacodynamics of Voriconazole for Invasive Pulmonary <i>Scedosporiosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	5
64	Posaconazole MIC Distributions for <i>Aspergillus fumigatus</i> Species Complex by Four Methods: Impact of <i>cyp51A</i> Mutations on Estimation of Epidemiological Cutoff Values. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	30
65	A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 280-286.	3.0	28
66	Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis. <i>Medical Mycology</i> , 2018, 56, S42-S59.	0.7	27
67	<i>Scedosporium</i> and <i>Lomentospora</i> : an updated overview of underrated opportunists. <i>Medical Mycology</i> , 2018, 56, S102-S125.	0.7	186
68	Cutaneous lesions and hemiparesis in a kidney transplant recipient. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 246-248.	0.5	0
69	Ecology of <i>Scedosporium</i> Species: Present Knowledge and Future Research. <i>Mycopathologia</i> , 2018, 183, 185-200.	3.1	66
70	Sequence analysis of isolates of <i>Aspergillus</i> from patients with chronic and allergic aspergillosis reveals a spectrum of cryptic species. <i>Future Microbiology</i> , 2018, 13, 1557-1563.	2.0	8
71	Eighty Years of <i>Mycopathologia</i> : A Retrospective Analysis of Progress Made in Understanding Human and Animal Fungal Pathogens. <i>Mycopathologia</i> , 2018, 183, 859-877.	3.1	21
72	Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	33

#	ARTICLE	IF	CITATIONS
73	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 516.	3.5	66
74	Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives. <i>Respiration</i> , 2018, 96, 159-170.	2.6	85
75	Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India. <i>Journal of Fungi (Basel, Tj ETQq1 1 0.784314 rgBT /Ove</i>	3.5	145
76	Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. <i>Emerging Infectious Diseases</i> , 2018, 24, .	4.3	89
77	A prospective international <i>Aspergillus terreus</i> survey: an EFISC, ISHAM and ECMM joint study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 776.e1-776.e5.	6.0	42
78	Case Series Study of Invasive Pulmonary Aspergillosis. <i>Mycopathologia</i> , 2017, 182, 505-515.	3.1	4
79	Development and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	15
80	The global problem of antifungal resistance: prevalence, mechanisms, and management. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e383-e392.	9.1	670
81	First isolation of <i>Conidiobolus</i> sp. in a respiratory sample of a patient in Europe. <i>Clinical Microbiology and Infection</i> , 2017, 23, 834.	6.0	4
82	<i>Saksena</i> <i>erythrospora</i> , an emerging mucoralean fungus causing severe necrotizing skin and soft tissue infections – a study from a tertiary care hospital in north India. <i>Infectious Diseases</i> , 2017, 49, 170-177.	2.8	43
83	Molecular identification, antifungal resistance and virulence of <i>Cryptococcus neoformans</i> and <i>Cryptococcus deneoformans</i> isolated in Seville, Spain. <i>Mycoses</i> , 2017, 60, 40-50.	4.0	40
84	Unraveling the Enzymatic Basis of Wine –Flavorome–: A Phylo-Functional Study of Wine Related Yeast Species. <i>Frontiers in Microbiology</i> , 2016, 7, 12.	3.5	98
85	Triazole Resistance in <i>Aspergillus</i> spp.: A Worldwide Problem?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2016, 2, 21.	3.5	108
86	Environmental Screening for the <i>Scedosporium apiospermum</i> Species Complex in Public Parks in Bangkok, Thailand. <i>PLoS ONE</i> , 2016, 11, e0159869.	2.5	16
87	Fungal Keratitis Due to <i>Beauveria bassiana</i> in a Contact Lenses Wearer and Review of Published Reports. <i>Mycopathologia</i> , 2016, 181, 745-752.	3.1	14
88	Diagnostics and susceptibility testing in <i>Aspergillus</i> . <i>Future Microbiology</i> , 2016, 11, 315-328.	2.0	21
89	Pathogenicity of <i>Candida albicans</i> isolates from bloodstream and mucosal candidiasis assessed in mice and <i>Galleria mellonella</i> . <i>Journal De Mycologie Medicale</i> , 2016, 26, 1-8.	1.5	32
90	Chaetomium-like fungi causing opportunistic infections in humans: a possible role for extremotolerance. <i>Fungal Diversity</i> , 2016, 76, 11-26.	12.3	24

#	ARTICLE	IF	CITATIONS
91	SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2015, 57, 57-64.	1.1	127
92	Fungal necrotizing fasciitis, an emerging infectious disease caused by <i>Apophysomyces</i> (Mucorales). <i>Revista Iberoamericana De Micologia</i> , 2015, 32, 93-98.	0.9	38
93	Changing Epidemiology of Mucoralean Fungi: Chronic Cutaneous Infection Caused by <i>Mucor irregularis</i> . <i>Mycopathologia</i> , 2015, 180, 181-186.	3.1	8
94	Rapid Development of <i>Candida krusei</i> Echinocandin Resistance during Caspofungin Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6975-6982.	3.2	50
95	Burden of serious fungal infections in Spain. <i>Clinical Microbiology and Infection</i> , 2015, 21, 183-189.	6.0	54
96	<i>Candida parapsilosis</i> , <i>Candida orthopsilosis</i> , and <i>Candida metapsilosis</i> virulence in the non-conventional host <i>Galleria mellonella</i> . <i>Virulence</i> , 2014, 5, 278-285.	4.4	73
97	Analysis of the Protein Domain and Domain Architecture Content in Fungi and Its Application in the Search of New Antifungal Targets. <i>PLoS Computational Biology</i> , 2014, 10, e1003733.	3.2	25
98	Antifungal Susceptibility Profile of Cryptic Species of <i>Aspergillus</i> . <i>Mycopathologia</i> , 2014, 178, 427-433.	3.1	108
99	Disseminated Infection due to <i>Saksenaea vasiformis</i> Secondary to Cutaneous Mucormycosis. <i>Mycopathologia</i> , 2014, 177, 97-101.	3.1	11
100	Ribosomic DNA intergenic spacer 1 region is useful when identifying <i>Candida parapsilosis</i> spp. complex based on high-resolution melting analysis. <i>Medical Mycology</i> , 2014, 52, 472-481.	0.7	12
101	<i>Candida tropicalis</i> Antifungal Cross-Resistance Is Related to Different Azole Target (Erg11p) Modifications. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4769-4781.	3.2	96
102	DNA barcoding in <l>Mucorales</l>: an inventory of biodiversity. <i>Personia: Molecular Phylogeny and Evolution of Fungi</i> , 2013, 30, 11-47.	4.4	219
103	Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3380-3387.	3.2	206
104	Multilocus sequence typing of <i>Candida albicans</i> isolates from candidemia and superficial candidiasis in Israel. <i>Medical Mycology</i> , 2013, 51, 755-758.	0.7	13
105	Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2509-2512.	3.9	19
106	Fks1 and Fks2 Are Functionally Redundant but Differentially Regulated in <i>Candida glabrata</i> : Implications for Echinocandin Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6304-6309.	3.2	113
107	Direct Analysis and Identification of Pathogenic <i>Lichtheimia</i> Species by Matrix-Assisted Laser Desorption Ionization- ⁺ Time of Flight Analyzer-Mediated Mass Spectrometry. <i>Journal of Clinical Microbiology</i> , 2012, 50, 419-427.	3.9	75
108	Reclassification of the <i>Candida haemulonii</i> Complex as <i>Candida haemulonii</i> (<i>C. haemulonii</i> Group I), <i>C. duobushaemulonii</i> sp. nov. (<i>C. haemulonii</i> Group II), and <i>C. haemulonii</i> var. <i>vulnera</i> var. nov.: Three Multiresistant Human Pathogenic Yeasts. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3641-3651.	3.9	201

#	ARTICLE	IF	CITATIONS
109	Current section and species complex concepts in <i>Aspergillus</i> : recommendations for routine daily practice. <i>Annals of the New York Academy of Sciences</i> , 2012, 1273, 18-24.	3.8	39
110	EUCAST and CLSI: How to Assess in Vitro Susceptibility and Clinical Resistance. <i>Current Fungal Infection Reports</i> , 2012, 6, 229-234.	2.6	18
111	Cutaneous infection by <i>Phomopsis longicolla</i> in a renal transplant recipient from Guinea: first report of human infection by this fungus. <i>Transplant Infectious Disease</i> , 2011, 13, 204-207.	1.7	49
112	Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3075-3083.	3.2	50
113	Pharmacodynamics of Echinocandins against <i>Candida glabrata</i> : Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4880-4887.	3.2	42
114	Antifungal susceptibility profile of clinical <i>Alternaria</i> spp. identified by molecular methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2585-2587.	3.0	17
115	Antifungal Susceptibility Profile of Human-Pathogenic Species of <i>Lichtheimia</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3058-3060.	3.2	26
116	Comparison of the Vitek 2 Antifungal Susceptibility System with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest Techniques for In Vitro Detection of Antifungal Resistance in Yeast Isolates. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1782-1786.	3.9	147
117	In vitro activity of nine antifungal agents against clinical isolates of <i>Aspergillus calidoustus</i> . <i>Medical Mycology</i> , 2010, 48, 97-102.	0.7	40
118	Molecular identification and susceptibility profile in vitro of the emerging pathogen <i>Candida kefyr</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 116-119.	1.8	22
119	<i>Aspergillus alliaceus</i> and <i>Aspergillus flavus</i> co-infection in an acute myeloid leukemia patient. <i>Medical Mycology</i> , 2010, 48, 995-999.	0.7	22
120	Species Recognition and Clinical Relevance of the Zygomycetous Genus <i>Lichtheimia</i> (syn. <i>Absidia</i> Pro Parte, <i>Mycocladius</i>). <i>Journal of Clinical Microbiology</i> , 2010, 48, 2154-2170.	3.9	121
121	Disseminated Fusariosis Caused by <i>Fusarium verticillioides</i> in an Acute Lymphoblastic Leukemia Patient after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Microbiology</i> , 2009, 47, 278-281.	3.9	28
122	Species Identification and Antifungal Susceptibility Patterns of Species Belonging to <i>Aspergillus</i> Section <i>Nigri</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4514-4517.	3.2	70
123	In Vitro Activities of Various Antifungal Drugs against <i>Aspergillus terreus</i> : Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 794-795.	3.2	62
124	Activity of Posaconazole and Other Antifungal Agents against <i>Mucorales</i> Strains Identified by Sequencing of Internal Transcribed Spacers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1686-1689.	3.2	77
125	In vitro activity of antifungals against Zygomycetes. <i>Clinical Microbiology and Infection</i> , 2009, 15, 71-76.	6.0	79
126	Infections due to <i>Phialemonium</i> species: case report and review. <i>Medical Mycology</i> , 2009, 47, 766-774.	0.7	24

#	ARTICLE	IF	CITATIONS
127	Identificación molecular y sensibilidad a los antifúngicos de cepas de <i>Trichosporon</i> aisladas en un hospital de Brasil. <i>Revista Iberoamericana De Micología</i> , 2008, 25, 221-225.	0.9	47
128	Clinical relevance of resistance to antifungals. <i>International Journal of Antimicrobial Agents</i> , 2008, 32, S111-S113.	2.5	22
129	Susceptibility Testing and Molecular Classification of <i>Paecilomyces</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2926-2928.	3.2	72
130	<i>Aspergillus</i> Section <i>Fumigati</i> : Antifungal Susceptibility Patterns and Sequence-Based Identification. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1244-1251.	3.2	233
131	In Vitro Activities of 35 Double Combinations of Antifungal Agents against <i>Scedosporium apiospermum</i> and <i>Scedosporium prolificans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1136-1139.	3.2	72
132	Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2468-2472.	3.2	196
133	Prevalence and Susceptibility Profile of <i>Candida metapsilosis</i> and <i>Candida orthopsilosis</i> : Results from Population-Based Surveillance of Candidemia in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1506-1509.	3.2	126
134	Antifungal susceptibility profile of clinical <i>Fusarium</i> spp. isolates identified by molecular methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 805-809.	3.0	191
135	Time of Incubation for Antifungal Susceptibility Testing of <i>Aspergillus fumigatus</i> : Can MIC Values Be Obtained at 24 Hours?. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4502-4504.	3.2	13
136	Prevalence and Susceptibility Testing of New Species of <i>Pseudallescheria</i> and <i>Scedosporium</i> in a Collection of Clinical Mold Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 748-751.	3.2	54
137	Genotype distribution of clinical isolates of <i>Trichosporon asahii</i> based on sequencing of intergenic spacer 1. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 435-440.	1.8	36
138	New resistance mechanisms to azole drugs in <i>Aspergillus fumigatus</i> and emergence of antifungal drugs-resistant <i>A. fumigatus</i> typical strains. <i>Medical Mycology</i> , 2006, 44, 367-371.	0.7	37